Abrysvo and ASCO News

New FDA Approvals

Get our free download! Implementing AMA Style – 8 Things to Get Right

This episode covers the latest FDA approvals from May 29 to Jun 2, 2023. Here are the key highlights:

Pfizer's RSV vaccine, Abrysvo, has received FDA approval for use in adults aged 60 years or older, aimed at preventing lower respiratory tract disease caused by the RSV virus, based on results from the Phase 3 RENOIR clinical trial.

Given Memorial day on May 29, it was a light week at the FDA, so we included dome reporting from this week's ASCO annual meeting:

The KEYNOTE-671 Phase 3 study presented at ASCO showed that adding pembrolizumab to neoadjuvant platinum-based chemotherapy, followed by adjuvant therapy after surgery, improved event-free survival in patients with early-stage non-small cell lung cancer, providing strong support for using PD-1/PD-L1 inhibitors in the neoadjuvant and adjuvant settings.

The DUO-O Phase 3 trial at ASCO revealed that a combination therapy of bevacizumab, durvalumab, and olaparib showed significantly better progression-free survival compared to bevacizumab monotherapy in newly diagnosed advanced ovarian cancer patients without BRCA mutations.

The NATALEE Phase 3 study presented at ASCO found that combining ribociclib, a CDK4/6 inhibitor, with endocrine therapy improved invasive disease-free survival in patients with stage IIB or III HR-positive/HER2-negative early breast cancer compared to endocrine therapy alone.

Brought to you by Nichols Reports. Check out our reports to help you get up and running with all the latest therapeutic agents within various medical specialties here.

Also brought to you by Nascentmc.com. A group of MD- and PhD-level medical writers serving the continuing medical education industry and meeting medical writing deadlines with excellence and enthusiasm.

Intro and outro musicGarden Of Love by Pk jazz Collective